Cranbury Connects™
Contact Cranbury Connects
Phone: 888-213-8747
Help is Available
At Cranbury Connects, we understand that managing treatment is complex, and we are here to help support your family through the process of gaining access to the medication your healthcare provider has prescribed. When you enroll into Cranbury Connects, you will be connected with a dedicated Care Coordinator who will be your direct point of contact to support you throughout your journey with deflazacort suspension. The Care Coordinator can answer general questions, help you stay on track with treatment, and check in routinely to offer support.
Together with our Specialty Pharmacy, we’ll work to:
Verify your insurance benefits and work with you and your healthcare provider to manage insurance requirements throughout treatment.
Review your eligibility for Financial Assistance Programs based on your insurance coverage and out-of-pocket costs.
Obtain Prior Authorization (PA) and support the appeals process (if necessary) in collaboration with your healthcare provider.
Coordinate with you to receive your first prescription as well as monthly refills. We’ll also address any questions you might have for the pharmacist.
Access & Support for Duchenne Muscular Dystrophy Patients
Cranbury Pharmaceuticals is committed to raising awareness, improving access, and providing support for families affected by Duchenne Muscular Dystrophy. Hear more about this mission from our team members:
We recognize that prioritizing awareness and providing support for patients within the community who suffer from Duchenne’s muscular dystrophy is crucial.
Increasing awareness is key in Muscular Dystrophy since it can drive earlier recognition and diagnosis. With an early diagnosis, treatment can start and help delay disease progression – improving the life of the patient.
Support is also key. Duchenne Muscular Dystrophy is a devastating disease, and families need support navigating the complex process of gaining treatment. Our Cranbury Pharmaceuticals generic team offers something new to these families. An AB-rated generic product at a lower price than the brand. In addition to a lower cost alternative Cranbury Pharmaceuticals has also added Cranbury Connects, a patient services program which provides support and financial assistance to these families. Our Care Coordinator is a single point of contact for patients and families along with prescriber offices to ensure the process of obtaining deflazacort suspension is as straightforward as possible.
In June 2024, Cranbury Pharmaceuticals debuted our FDA-approved ANDA for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne muscular dystrophy. We're bringing a more affordable option to patients that have Duchenne Muscular Dystrophy - and there is a substantial financial burden on families that have children with this disease. With the generic deflazacort oral suspension now available to patients in the U.S., we are looking to apply this approach of extra support through care coordinators and infrastructural organization to other significantly complex rare diseases.
– Janet Penner, President, Generics Division
As a generic manufacturer, we often find ourselves competing based on two key factors: continuity of supply and lowest price. With now entering the muscular dystrophy space, we have adopted a new key differentiator to our generics business: patient care.
Navigating muscular dystrophy is very complex and without proper support can often feel overwhelming to many families. The work we’re doing at Tris, developing complex treatments, launching Deflazacort Oral Suspension (AB Rated to Emflaza®) and providing impactful patient engagement through care management is groundbreaking work in our generics market.
I’m proud of the entrepreneurial spirit Tris Pharma embodies as well as the dedication towards creating meaningful awareness and positive impact in the muscular dystrophy space.
– Kevin Walker, Vice President, Generic Sales
Process
Cranbury Connects will confirm the information on your Prescription Start Form. When we receive your prescription, we acknowledge receipt with your healthcare provider, and then reach out to you to confirm your information.
Next, we do a complete and accurate verification of your insurance benefits. We work with your insurance provider(s) and your healthcare provider to confirm your coverage and any out-of-pocket costs for you. This will include any Prior Authorizations and Appeals that are necessary.
Once insurance coverage and out of pocket costs are confirmed, we will review this with you and identify any financial assistance programs that you might be eligible for.
Your first prescription will be sent to you from one of our dedicated specialty pharmacies, and they will coordinate monthly refills or answer questions you might have for the pharmacist.
Financial Assistance
Cranbury Connects recognizes that out-of-pockets costs for specialty pharmaceuticals can be expensive. Once we have completed your insurance benefit verification, we can go over the Cranbury Connects assistance programs that you might be eligible for. Enrollment in Cranbury Connects is required to qualify for financial assistance benefits.
Cranbury Connects offers three programs:
Bridge Program
The Bridge Program allows for a temporary supply of medication for free while newly enrolled patients are awaiting insurance coverage verification.
The Copay Assistance Program*
The Copay Assistance Program is for commercially insured patients with high out of pocket costs associated with their prescription.
Patient Assistance Program**
The Patient Assistance Program offers free product for uninsured or underinsured patients who meet certain financial income qualifications.
If you need additional financial support, we’ll refer you to other charitable foundations that may be able to help.
* Not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid or Medicare (including Medicare Part D), or where prohibited by law.
** Patients enrolled in an Alternate Funding Program are not eligible for the Patient Assistance Program.
Get Started
You may submit the prescription to one of our limited distribution specialty pharmacies using either the Prescription Start Form or an electronic prescription. If using the start form, please ensure both the prescriber and patient/family have completed their respective sections. The form has two sides- sign where indicated and fax it to the number provided on the form. Alternatively, you can submit the prescription electronically direct to the pharmacy, and the patient/family can complete a separate consent form to enroll into Cranbury Connects.
PRESCRIPTION START FORM
PATIENT CONSENT FORM
NUEVA PRESCRIPCION
AUTORIZACION DEL PATIENTE
You are about to leave this site
You are about to leave Cranburypharma.com and enter a website operated by a third party. Would you like to continue?